Dolutegravir Tivicay News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dolutegravir tivicay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dolutegravir Tivicay Today - Breaking & Trending Today

Pediatric HIV: Trial Sets Tivicay Backbone as Best First-Line Option

email article
Dolutegravir (Tivicay)-based antiretroviral therapy in children with HIV infection was superior to efavirenz-based standard of care in the first-line setting in a prospective trial, researchers reported.
In her presentation at the virtual Conference on Retroviruses and Opportunistic Infections, Anna Turkova, MD, of University College London, added that in the second-line setting, it appears dolutegravir-based treatment is at least non-inferior to current treatment regimens.
Reporting for the ODYSSEY/PENTA-20 Trial team, she said the international, multicenter, randomized 96-week trials had 47 virologic failure events (14%) among children on dolutegravir compared with 75 (22%) among children on efavirenz, a difference that for this primary endpoint of the trial reached statistical significance ( ....

South Africa , Anna Turkova , Dolutegravir Tivicay , Sharon Hillier , University College London , University Of Pittsburgh School Medicine , Opportunistic Infections , Medpage Today , Pittsburgh School , Reverse Transcriptase , Hiv Infection , ஷரோன் ஹில்லியர் , பல்கலைக்கழகம் கல்லூரி லண்டன் , பல்கலைக்கழகம் ஆஃப் பிட்ஸ்பர்க் பள்ளி மருந்து , பிட்ஸ்பர்க் பள்ளி , எசைவீ தொற்று ,

United States HIV Infection Drug Market Report 2021-2026: Success Rate Associated with the Available Anti-retrovirals are Continuing to Expand at Historic Levels

United States HIV Infection Drug Market Report 2021-2026: Success Rate Associated with the Available Anti-retrovirals are Continuing to Expand at Historic Levels
February 24, 2021 08:03 ET
| Source:
Research and Markets
Research and Markets
Dublin, IRELAND
ResearchAndMarkets.com s offering.
US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026 report findings, it is concluded that the research and development pipelines for HIV drugs are growing at a high rate and on the brighter note, the success rate associated with the available antiretrovirals are continuing to expand at historic levels.
Nevertheless, this is boosting the researchers to build an overall strong frame for clinical activity and ultimately result in novel product launches in the upcoming years. It is estimated that the future novel products developed in the US bio-pharmaceutical companies and research center will a ....

Emtricitabine Emtriva , Atazanavir Cobicistat Evotaz , Didanosine Videx , Cobicistat Darunavir Emtricitabine Tenofovir , Abacavir Ziagen , Raltegravir Isentress , Cobicistat Darunavir Prezcobix , Tipranavir Aptivus , Rilpivirine Edurant , Nelfinavir Viracept , Enfuvirtide Fuzeon , Cobicistat Tybost , Maraviroc Selzentry , Tenofovir Disoproxil Fumarate Viread , Fostemsavir Rukobia , Darunavir Prezista , Doravirine Pifeltro , Dolutegravir Tivicay , Efavirenz Sustiva , Ibalizumab Uiyk Trogarzo , Amprenavir Agenerase , Fosamprenavir Lexiva , Etravirine Intelence , Atazanavir Reyataz , Drug Market , Sales Insight ,